Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neutrophilia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Neutrophilia. Displaying page 1 of 1.
    EudraCT Number: 2008-002854-39 Sponsor Protocol Number: CAIN457A2104 Start Date*: 2009-01-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placeb...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004231-37 Sponsor Protocol Number: 1368-0013 Start Date*: 2019-01-22
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presentin...
    Medical condition: Generalized Pustular Psoriasis (GPP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004163-39 Sponsor Protocol Number: HSJD-LIT-05 Start Date*: 2005-11-14
    Sponsor Name:Hospital Sant Joan de Déu
    Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ...
    Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002680-26 Sponsor Protocol Number: RP-L201-0218 Start Date*: 2018-11-27
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lenti...
    Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018137 Genetic anomalies of leukocytes LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002584-90 Sponsor Protocol Number: D1511C00002 Start Date*: 2005-08-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007244-33 Sponsor Protocol Number: LPA112046 Start Date*: 2009-04-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003628-18 Sponsor Protocol Number: 000000 Start Date*: 2020-09-29
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-013163-18 Sponsor Protocol Number: R014 Start Date*: 2009-08-11
    Sponsor Name:REVOTAR Biopharmaceuticals AG
    Full Title: A double-blind, placebo controlled, randomized, cross-over Phase IIa study to evaluate the effect of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.
    Medical condition: healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004584-22 Sponsor Protocol Number: D0520C00003 Start Date*: 2007-11-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000517-33 Sponsor Protocol Number: RP-L201-0318 Start Date*: 2020-07-14
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Len...
    Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018137 Genetic anomalies of leukocytes LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003331-32 Sponsor Protocol Number: AZI003 Start Date*: 2013-06-18
    Sponsor Name:KULeuven and University Hospitals Leuven
    Full Title: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTA...
    Medical condition: EARLY LUNG ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050437 Prophylaxis against heart and lung transplant rejection LLT
    14.1 10022891 - Investigations 10016547 FEV LLT
    14.1 10042613 - Surgical and medical procedures 10050433 Prophylaxis against lung transplant rejection LLT
    14.1 10022891 - Investigations 10006414 Bronchial biopsy abnormal LLT
    14.1 10022891 - Investigations 10025041 Lung biopsy abnormal LLT
    14.1 10022891 - Investigations 10016549 FEV 1 abnormal LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    14.1 10021428 - Immune system disorders 10049237 Acute cellular rejection LLT
    14.1 10021428 - Immune system disorders 10066543 Acute allograft rejection LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039008 Reversible airways obstruction NOS LLT
    14.1 10021428 - Immune system disorders 10019319 Heart-lung transplant rejection PT
    14.1 10022891 - Investigations 10016550 FEV 1 decreased LLT
    14.1 10022891 - Investigations 10057799 Computerised tomogram thorax abnormal PT
    14.1 10022891 - Investigations 10063078 Bronchoalveolar lavage abnormal PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068956 Respiratory tract inflammation PT
    14.1 100000004862 10049083 Respiratory tract infection NOS LLT
    14.1 10022891 - Investigations 10016553 FEV 1 low LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003204-39 Sponsor Protocol Number: BT–L-CsA–301–SLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003205-25 Sponsor Protocol Number: BT–L-CsA–302–DLT Start Date*: 2019-01-09
    Sponsor Name:BREATH Therapeutics Inc.
    Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA...
    Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:21:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA